Pharmaceutical

Pfizer’s Ngenla finally secures FDA approval following a rocky road to market

Pfizer has announced that the FDA has approved Ngenla (somatrogon-ghla), a paediatric growth hormone deficiency treatment.

Jun 29, 2023 - 20:00
Pfizer’s Ngenla finally secures FDA approval following a rocky road to market
Pfizer has announced that the FDA has approved Ngenla (somatrogon-ghla), a paediatric growth hormone deficiency treatment.
Read the original article

Tags:

Previous Article

Genprex’s Reqorsa gene therapy secures another FDA fast-track designation

Next Article

Cellusion shares pipeline update for eye disease stem cell therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Xcovery edges closer to FDA approval for NSCLC ALK inhibitor

Xcovery edges closer to FDA approval for NSCLC ALK inhi...

Mar 16, 2024

Alzheimer’s disease not forgotten as FDA oversees record number of designations awarded

Alzheimer’s disease not forgotten as FDA oversees recor...

Apr 4, 2023

Santhera fully divests rare eye disease drug Raxone to Chiesi

Santhera fully divests rare eye disease drug Raxone to ...

Jul 31, 2023